Gilead Sciences In-Depth Value Investment Research

Hunting ten-year five-baggers among great growth stocks — pressing the upside question: "Can it get much bigger?"

• QHow high is its market ceiling? Is it expanding an existing pie, or creating an entirely new market?5/10

  A

  The ceiling is real, but Gilead's main battlefield is closer to expanding and defending a large existing pie than creating a new market from scratch. The only axis with a genuine “new market creation” quality is long-acting HIV prevention, or PrEP.

  Start with the core base. Gilead is a mature pharmaceutical company whose cash cow is HIV. Full-year 2025 revenue was $29.443 billion, of which HIV products contributed $20.8 billion, and Biktarvy alone contributed $14.3 billion. By Q1 2026, Biktarvy's share of the U.S. HIV treatment market had exceeded 52%. In other words, the HIV treatment pie is already close to mature, and Gilead is already the clear leader. What it can do on this line is defend share with next-generation molecules and counter long-acting competitors, not multiply the total market severalfold. This is a classic case of defending a large existing pie, not opening virgin territory.

  The area with real “new market creation” characteristics is long-acting HIV prevention. Gilead's twice-yearly injectable Yeztugo (lenacapavir) was approved by the FDA on June 18, 2025. It recorded only about $150 million in launch revenue in 2025, but had risen to $166 million in Q1 2026, up 72% sequentially, and the company raised full-year guidance to $1 billion. From a ceiling perspective, this is the piece that can support imagination: Mizuho raised its global peak-sales estimate for lenacapavir from $4–5 billion to about $8 billion, and Citi believes Gilead's PrEP portfolio could take more than 60% share of the U.S. PrEP market by the mid-2030s. Twice-yearly dosing, turning prevention into a vaccine-like adherence experience, does have the potential to reshape the PrEP market structure. Still, it is raising penetration in an existing HIV prevention use case, not creating a never-before-seen disease category.

  As for oncology (Trodelvy, Yescarta, Tecartus, and acquired anito-cel) and inflammation, those are existing markets Gilead is trying to enter, and they are already highly crowded. Trodelvy's Q1 2026 sales of $402 million, up 37% year over year, were impressive, but cell therapy and ADCs are red oceans packed with leading pharmaceutical companies. This is taking meat from someone else's plate, not opening unoccupied ground.

  Measured with Baillie Gifford LTGG's “five times in ten years” yardstick, Gilead's ceiling is high enough to house a good company worth hundreds of billions of dollars in market cap. But its growth comes more from maintaining leadership in large existing markets plus scaling the incremental long-acting prevention axis. It lacks the explosive structure of creating a brand-new trillion-dollar market. Honestly, on this dimension it is primarily expanding and defending an existing pie, with new-market creation as a secondary element. It is not the kind of new-market pioneer LTGG loves most.

  Jun 11, 2026
• QCan its revenue at least double over the next five years? Will growth mainly be driven by volume, price, or new businesses?4/10

  A

  Almost certainly not. For Gilead to double revenue over the next five years, from about $29.4 billion to about $59.0 billion, it would need roughly a 15% five-year compound growth rate, far above its realistic trajectory. The main growth driver is volume, from long-acting prevention scaling and new pipeline/acquired assets launching, plus a small amount of price, but the scale is not enough to support a doubling.

  Look first at the historical and current growth baseline. Gilead's revenue rose from about $27.3 billion in 2021 to $29.443 billion in 2025, a four-year compound growth rate of only about 2%. Full-year 2025 revenue also grew just 2% year over year. Q1 2026 revenue grew 4% to $6.960 billion. More importantly, the company's own 2026 guidance calls for total product sales including Veklury of about $30.0–30.4 billion, and base business sales excluding Veklury of about $29.4–29.8 billion, implying 5–6% growth. A company whose management guides to only 5–6% growth would need its growth rate to jump abruptly to 15% and stay there for five straight years to double revenue. That does not fit its product structure or history.

  Now break down what would drive growth:

  • Mostly volume, with price constrained. HIV treatment, led by Biktarvy, is already the leader with share above 52%. It relies on prescription inertia to hold its position, leaving limited volume upside. On price, U.S. rebates, insurance coverage, IRA reform, and competition all suppress pricing. The company's auditor specifically lists rebate estimates in revenue as a critical audit matter, which shows this is not a business where management can raise prices at will. Gilead raised its 2026 HIV growth guidance from 6% to 8%, which is respectable, but still single digit.

  • The real incremental axis is long-acting prevention. Yeztugo's 2026 guidance is $1 billion, with optimistic peak estimates around $8 billion. Even if this line reaches $3–4 billion within five years, it would lift the total pie by only a bit more than 10%, not enough to drive a doubling on its own.

  • Oncology/acquired assets are options, not certain increments. Trodelvy's Q1 2026 $402 million, +37%, is a bright spot. anito-cel from the Arcellx acquisition, Tubulis's ADC, and Ouro's bispecific antibody are still in clinical development or only newly commercialized. Whether they become new growth engines depends on approval and uptake, with real failure risk.

  Add it up: a reasonable five-year scenario is single-digit HIV growth, several billion dollars from long-acting prevention, and gradual scaling of oncology/new assets, taking revenue from about $29.4 billion to roughly $35.0–42.0 billion, or about 4–7% annualized. That is steady growth, but far from a doubling.

  Using Baillie Gifford's yardstick, LTGG wants explosive growth stocks whose revenue can at least double in five years. Gilead clearly is not in that bucket. Its growth is real and volume-driven, but moderate. A five-year doubling is not “realistic but requires effort”; it is almost impossible. This dimension deserves a low score. Single-digit growth should not be dressed up as doubling potential just to fit a growth narrative.

  Jun 11, 2026
• QFive years from now, what will take over as the next growth engine? Does this “second curve” exist today?5/10

  A

  The second curve does exist today, but more precisely it is multiple candidate curves that are still climbing and not yet validated, rather than one mature engine already able to take over from the HIV cash cow. The most promising is long-acting HIV prevention, followed by oncology (Trodelvy + cell therapy + ADC), but the latter remains far from becoming a second cash cow.

  First, establish why Gilead needs a second curve. Its revenue is highly dependent on HIV. In Q1 2026 total revenue of $6.960 billion, Biktarvy alone accounted for $3.361 billion (about 48%). For a company with nearly half its revenue concentrated in a single product, growth five years from now has to come from something new.

  Look at the candidate curves one by one:

  First candidate: long-acting HIV prevention (Yeztugo / lenacapavir), the most tangible and nearest. This line was approved only in June 2025. Q1 2026 sales were $166 million, up 72% sequentially, full-year guidance is $1 billion, U.S. payer coverage has reached about 95%, with 95% at zero out-of-pocket cost, and analysts' peak-sales imagination reaches about $8 billion. This is the highest-quality second curve: visible today and scaling quickly.

  Second candidate: oncology, present but still in the proof phase. Trodelvy generated $402 million in Q1 2026, up 37% year over year, and has established itself in second-line metastatic triple-negative breast cancer. Cell therapies Yescarta and Tecartus have commercial value, but the field is crowded. This is a real business, but still small in scale, two orders of magnitude away from replacing HIV at the $20.0 billion annual level.

  Third candidate: future curves “bought” through major 2026 acquisitions. Gilead moved aggressively in 2026: Arcellx (bringing in BCMA CAR-T anito-cel, with cash consideration of about $7.1 billion + CVR), Tubulis (ADC, about $3.15 billion upfront), and Ouro Medicines (BCMA×CD3 bispecific antibody, about $1.675 billion upfront, with Galapagos sharing 50%). Management disclosed on the Q1 call that total 2026 acquisition upfront payments were about $11.8 billion. These assets, including anito-cel, TUB-040, and OM-336, are mostly still in clinical development or newly commercialized. They are candidate curves bought with the balance sheet. The direction is right, but realization depends heavily on clinical and commercialization execution, with real risk of failure.

  Putting the three together, the honest conclusion is that the second curve is not absent; it exists, but all of the curves are still young. Long-acting prevention is closest to being formed. Oncology and acquired assets are promising but unvalidated options. From a Baillie Gifford perspective, an ideal second curve should be clearly visible today and have the scale and certainty to become the next main engine. Gilead satisfies “visible,” but not yet “large and certain enough to take over.” That is why it looks more like a cash cow plus several call options than a company with two engines flying together. A neutral-to-positive assessment is fair here, but it should not be elevated into “the second curve is already mature.”

  Jun 11, 2026
• QWhat is its core competitive advantage? Will this moat widen or narrow over the next three to five years?6/10

  A

  Gilead's core moat is patent/regulatory barriers in HIV + long-term clinical evidence + physician prescribing inertia + scaled R&D and commercialization capability. It is a real moat, but it is highly concentrated in HIV. Over the next three to five years, the moat is more likely to diverge than simply widen overall: the core barriers in HIV treatment face gradual erosion from long-acting competitors, while the new moat in long-acting prevention has room to extend. The oncology/inflammation moat is still under construction.

  Start with where the moat's current strength comes from. The hardest piece is Biktarvy's dominant position in HIV treatment: Q1 2026 U.S. share above 52%, and full-year HIV revenue of $20.8 billion. This stickiness comes from the chronic-disease combination of long-term safety data, physician familiarity, and patient concerns about switching, layered on top of patent protection. It is harder to dislodge than a consumer brand. This is a real and measurable moat, not a story.

  But the question of whether it widens or narrows over the next three to five years has to be forward-looking; historical share cannot simply be extrapolated:

  Narrowing pressure on HIV treatment: long-acting competitors are rising. Key competitor GSK/ViiV's long-acting injectable Cabenuva generated £1.402 billion in 2025 sales, up 42%, while long-acting PrEP Apretude generated £439 million, up 62%. In the U.S., long-acting injectables already account for about 30% of ViiV's HIV sales. Treatment and prevention are both migrating from daily oral drugs to long-acting regimens. That is the biggest structural headwind for Biktarvy, a daily oral cash cow. Biktarvy's moat is wide today, but the industry shift toward long-acting treatment will pressure it over 3–5 years.

  Widening opportunity in HIV prevention: Gilead has jumped to long-acting itself. Gilead's twice-yearly injectable Yeztugo (lenacapavir) turns “two injections per year” into a new pillar of the moat, with Q1 2026 +72% sequential growth and payer coverage of about 95%. Citi estimates Gilead's PrEP portfolio could take more than 60% share of the U.S. PrEP market by the mid-2030s. In other words, Gilead is not passively taking hits in the long-acting wave; it is using lenacapavir to widen the moat on the prevention side. This is the most positive piece of its forward moat.

  Still under construction in oncology/inflammation: the moat is not yet formed. Cell therapy and ADCs are crowded arenas. BMS stated directly in its annual report that Abecma's 2025 U.S. revenue fell 14% because competition in BCMA-targeted therapies intensified. That is the same red ocean Gilead is entering after acquiring anito-cel. There is no real moat here yet; the trench is being dug, but it is not deep.

  Item by item, consistent with the report's framework: brand is medium (strong with physicians, not a mass consumer brand), scale advantage is strong, switching costs are strong in HIV, patent/regulatory barriers are strong, network effects are nearly absent, and cost advantage is weak to medium. In aggregate, moat strength is roughly “HIV sub-business 4/5, whole group 3/5”: real, but not comprehensive or balanced.

  The honest conclusion: this is a real moat, but it is high-barrier oligopolistic competition, not an unassailable monopoly. Competitors cannot copy a second Biktarvy, but they can, as ViiV already has, create effective alternatives. Over the next three to five years, the most likely picture is that the HIV treatment moat is slowly eroded by the long-acting trend, the prevention moat is widened by lenacapavir, and whether oncology can dig a new moat remains unknown. That is divergence, not a clean overall widening. From a Baillie Gifford perspective, this dimension deserves a neutral assessment: real but concentrated, with identifiable narrowing pressure. It should not be upgraded as if the group-wide moat is widening overall.

  Jun 11, 2026
• QIf the core business is disrupted, does it have the DNA to reinvent itself? How does it handle mistakes and bad news?5/10

  A

  If the HIV cash cow is disrupted, Gilead does have reinvention DNA. It has already completed one major transformation, from hepatitis C to HIV, and is now using heavy acquisitions to actively position for the next chapter in oncology/inflammation. Its attitude toward mistakes and bad news is financially honest, with adequate disclosure, but it looks more like steady correction by mature professional managers than founder-style all-in resolve. The DNA is acceptable, but it is not the strong regenerative power LTGG prizes, where a company can be reborn even after the core is disrupted.

  First, make explicit the hidden premise in this linked question: reinvention DNA when the core business is disrupted. To judge whether a company has this DNA, two things matter: whether it has truly changed its main engine before, and whether it is actively preparing for the next disruption today.

  Historical evidence: Gilead has changed engines. Its previous cash cow was hepatitis C (Sovaldi/Harvoni). Hepatitis C later naturally shrank because a cure means patients leave the pool, and the company successfully shifted its center of gravity to HIV. HIV annual revenue has now reached $20.8 billion. The report also specifically notes that Veklury (remdesivir) lifted revenue during the pandemic and then naturally declined. The company's ability to keep operating cash flow stable through large revenue swings, with 2025 operating cash flow of $10.019 billion, itself shows organizational resilience: when one engine stalls, it can switch to another.

  Current evidence: it is actively preparing for disruption. Facing the identifiable disruption of HIV treatment migrating to long-acting regimens, Gilead has not simply defended daily oral Biktarvy. It is betting on two lines: internally developed long-acting prevention Yeztugo (lenacapavir, Q1 2026 +72% sequentially) and about $11.8 billion upfront in 2026 acquisitions of oncology/inflammation assets, including Arcellx's anito-cel, Tubulis's ADC, and Ouro's bispecific antibody. This is an active reinvention posture. The method is buying rather than internally incubating, but it is clearly stocking ammunition for the day the core is disrupted.

  How it handles mistakes and bad news: financially honest, operationally steady. Gilead's accounting does not shy away from bad news. In 2024, large acquired IPR&D charges and impairments pushed GAAP net income down to only $480 million, while operating cash flow was still $10.8 billion. The company did not dress this up; it recognized the charges. The report also notes that annual report and 10-Q disclosures are reasonably full on impairments, competitive risks, customer concentration, and acquisition accounting. The auditor lists rebate estimates in revenue as a critical audit matter, and the company presents that plainly. These are positive signs that bad news is not hidden. Governance also includes share ownership requirements, a clawback policy, and a ban on hedging or pledging company stock; all serving executives satisfy the ownership requirements. The correction mechanism is institutionalized.

  But the ceiling of this DNA needs to be marked honestly. This is reinvention by a mature pharmaceutical company using its balance sheet to buy the future: controlled and steady, but lacking the founder-like regenerative force of betting the house on the next chapter. And acquisition-led reinvention carries its own risk. If management overpays or buys the wrong assets, reinvention can become permanent capital loss. That is the key risk to watch now.

  From a Baillie Gifford perspective, Gilead has this DNA and is using it. History validates one transition, the company is actively positioning today, and its financial treatment of mistakes and bad news is honest. That is acceptable and even mildly positive. But the reinvention path depends on successful external acquisitions, making it less certain than a top-tier growth company that can regenerate internally after its core is disrupted. A neutral-to-positive score, not a full score, is fair.

  Jun 11, 2026
• QDoes management, especially the founder, have a long-term view and deep alignment with the company? Is it willing to sacrifice current profit for five to ten years from now?4/10

  A

  Management is mature and professionalized. The governance framework is adequate, long-term incentives are in place, and management is willing to sacrifice current profit for five to ten years from now, as shown by the heavy acquisitions. But the alignment is at the professional-manager level, not founder level. There is no founder, and executives as a group own less than 1% of shares outstanding. That is far from the founder-level deep alignment Baillie Gifford most prefers.

  Separate the two parts of the question: how deep alignment is, and whether management is willing to sacrifice today for the long term.

  Alignment: adequate, but not founder-like deep alignment. Gilead has no controlling founder. It is a typical professionally managed company. The report discloses that as of February 28, 2026, CEO Daniel O'Day held about 1.969 million shares, while all current executives and directors together held about 3.696 million shares, in each case less than 1% of total shares outstanding. At the current share price of about $122, O'Day's stake is still a meaningful personal economic interest, roughly $240 million, so it is not fair to say he does not care about the stock price. But this is very different from Berkshire-like or founder-like alignment where personal fortune is deeply tied to the company. Baillie Gifford LTGG prefers long-tenured founder leadership with interests fused to the company's destiny. On this point, Gilead is best described as institutionally moderate alignment.

  Governance and incentives: institutionalized and somewhat long term. The company has executive share ownership requirements, and all serving NEOs had satisfied them by the end of 2025. It has a clawback policy, prohibits hedging and pledging company stock, and compensation metrics include long-term elements such as relative TSR and adjusted EPS growth. These are positive institutional signals that do not encourage short-termism, and they indicate a healthy governance structure.

  Willingness to sacrifice current profit for the long term: clearly yes, even somewhat aggressively. Gilead's answer here is clear. It is sacrificing current-period profit for future assets through major acquisitions. Upfront payments for 2026 acquisitions total about $11.8 billion, directly pushing 2026 GAAP/Non-GAAP profit into a loss range. The company's 2026 non-GAAP EPS guidance is a loss of $1.05 to $0.65 per share, including about $9.50 per share of acquisition charges; excluding those charges, guidance would be earnings of $8.45–8.85 per share. A company that willingly turns current reported profit negative to buy growth assets for the next decade is giving the strongest evidence that it will sacrifice near-term profit for five to ten years from now. It also maintains dividend discipline, with the per-share dividend rising from $2.84 in 2021 to $3.16 in 2025.

  But that willingness is a double-edged sword, and the risk must be stated honestly. Willingness to bet for the long term is a strength, but the question is whether the bets are right. Gilead's capital allocation is shifting from dividends plus moderate buybacks toward using the balance sheet and stock price to buy the future. The level of aggression has clearly risen, and these acquired assets, including anito-cel, ADCs, and bispecific antibodies, have not yet proven that they can create per-share intrinsic value. In other words, management has a long-term view and is willing to sacrifice today, but whether that long-term view turns into long-term returns is still unproven. That is what should be watched closely.

  From a Baillie Gifford perspective, this dimension is “adequate governance + long-term incentives + clear willingness to sacrifice current profit,” which is positive. But the absence of a founder and executive ownership below 1% keeps alignment at the professional-manager level, below the founder-level deep alignment LTGG prizes. A neutral-to-positive score, rather than a high score, is fair: it recognizes the real long-term posture without forcing a founder-style label onto a professional management team.

  Jun 11, 2026
• QIf it disappeared tomorrow, how much would customers miss it? Is its growth sustainable and not dependent on harming society or regulation?6/10

  A

  If Gilead disappeared tomorrow, patients would miss it badly. Its HIV medicines are indispensable and, to a large extent, cannot be instantly replaced. This is real social necessity. Its growth model is also a “treating disease and saving lives” model, fundamentally beneficial to society and not built on harming society for profit. But the “not dependent on regulation” part needs a discount: the life blood of pharmaceuticals is held by FDA approvals, patent protection, and the insurance/rebate system. Regulation is both its moat and the sword hanging overhead.

  First, make explicit the two hidden premises in this linked question: indispensability and social/regulatory sustainability.

  Indispensability: very high. Gilead is the de facto leader in global HIV treatment. Biktarvy's U.S. HIV treatment share is above 52%, and HIV products generated $20.8 billion in full-year 2025 revenue. HIV is a chronic disease requiring lifelong medication. Once patients are stable on a high-resistance-barrier regimen, interruption or forced switching creates real health risk. U.S. HIV treatment guidelines list the BIC/TAF/FTC regimen to which Biktarvy belongs as one recommended initial regimen for most people with HIV. That position, embedded in guidelines and supported by clinical trust and long-term safety data, means that if Gilead suddenly disappeared, no one could seamlessly replace the same supply and evidence base in the short term. Patients would miss it very much. Add the recent launch of long-acting prevention, Yeztugo, a twice-yearly injection, with payer coverage already around 95%, and its indispensability in the HIV prevention and treatment chain is deepening.

  Social sustainability: fundamentally positive. Gilead earns money by turning HIV from a fatal disease into a manageable chronic condition and making prevention feel more like a vaccine experience. Its growth is aligned with social benefit. It is not monetizing addiction, deception, or shifted externalities. This is fundamentally different from businesses whose growth depends on harming users or society. From an ESG and “would society miss it” perspective, it stands on solid ground.

  Regulatory sustainability: this is where the discount is necessary. Pharmaceutical growth cannot be independent of regulation. In fact, it depends deeply on regulation, and that double-edged sword is sharp on both sides:

  • On one side, regulation/patents are the moat: FDA approval and patent protection are prerequisites for the cash generation of core drugs such as Biktarvy.
  • On the other side, regulation is the sword overhead: in the U.S., net prices are squeezed by rebates, formularies, IRA reform, commercial insurance, and competing launches. The report specifically notes that Gilead's auditor listed rebate estimates in revenue as a critical audit matter in the 2025 audit report. That shows precisely that the company cannot raise prices whenever it wants; pricing power is materially constrained by regulators and payers.

  So the accurate answer to whether its growth is sustainable and not dependent on harming society or regulation is: growth does not harm society, which is a positive, but it is highly dependent on regulation. That is an industry feature rather than a flaw, yet it is a structural constraint. When policy changes, net prices and the profit pool can be reshaped.

  From a Baillie Gifford perspective, this is one of Gilead's relatively stronger dimensions: high indispensability, positive social value, benign growth model, and genuine “it would be missed tomorrow” quality. But “not dependent on regulation” is impossible in pharmaceuticals. The company's fate is deeply tied to FDA approvals, patents, insurance coverage, and rebates. That gives it a moat and systemic risk at the same time. A neutral-to-positive assessment, “high indispensability and social value, high regulatory dependence,” is fair. The fact that it saves lives should not lead us to ignore the constant regulatory/pricing sword.

  Jun 11, 2026
• QWhat are the unit economics of this business, including gross margin and incremental returns? Do they improve or worsen with scale? Where does the money it earns go?7/10

  A

  Unit economics are excellent: product gross margin is about 78%, operating margin about 34%, and capital expenditure is extremely low, less than 2% of revenue. This is a typical innovative-drug structure with high gross margin, light maintenance capital, and strong cash flow. As scale grows, the base business's unit economics remain excellent and even gain some leverage. But incremental returns now face a test because more of the money earned is going into high-priced acquisitions whose returns are not yet proven.

  Start with core unit economics, item by item:

  Gross margin is extremely high. 2025 product sales were $28.915 billion, and cost of goods sold was $6.234 billion, implying product gross margin of about 78.4%. This is the essence of the new-drug business: once a molecule is on the market, the marginal cost of selling one more box is very low.

  Operating margin is strong and capital intensity is very light. 2025 operating profit was $10.022 billion, for an operating margin of about 34%; full-year capital expenditure was only $563 million, less than 2% of revenue. That means maintaining the existing commercialization platform requires very little heavy capital. This is a very high-quality, light-maintenance-capital business.

  Cash conversion is better than accounting profit. 2025 operating cash flow was $10.019 billion, and free cash flow was about $9.456 billion, both above or matching GAAP net income of $8.510 billion. Even in the extreme year of 2024, when impairments pushed GAAP net income down to only $480 million, the company still generated $10.8 billion of operating cash flow. That shows real cash generation is much steadier than accounting profit.

  Do economics improve or worsen with scale? The base business improves slightly. The HIV platform is already built, and new products such as Yeztugo reuse the same sales force and payer negotiation network, so marginal margins are high and scale has positive leverage. But two types of incremental return must be separated honestly:

  • Organic incremental returns: high. Selling one more HIV/prevention drug is almost high gross margin falling directly into operating profit.
  • Acquisition-driven incremental returns: unproven, with rising risk. This is the most fragile part of the unit-economics story today.

  Where does the money it earns go? This is the part that must be scrutinized. Gilead's cash has three destinations: first, stable dividends, with the per-share dividend rising from $2.84 in 2021 to $3.16 in 2025; second, moderate buybacks, with about $1.922 billion repurchased in 2025 at an average price of $107.50 per share, per the report; third, increasingly aggressive acquisitions, with about $11.8 billion of 2026 acquisition upfront payments (Arcellx cash of about $7.1 billion, Tubulis upfront of about $3.15 billion, and Ouro upfront of about $1.675 billion).

  Put those two facts together and the key tension is clear: the business itself has excellent unit economics, but management is putting a large amount of free cash flow into external assets whose returns are not yet proven. If the acquired assets ultimately fail to generate ROIC above the cost of capital, which the report repeatedly says is the real point to watch after acquisitions, then excellent unit economics will be partially diluted by mediocre capital allocation. A good business is not necessarily good incremental compounding.

  From a Baillie Gifford perspective, Gilead scores high on business quality in this dimension. Gross margin, profit margin, cash conversion, and capital intensity are textbook-quality pharmaceutical economics. It is clearly stronger than growth companies whose gross margins have only just turned positive and that are still burning cash. But LTGG also looks at returns on reinvested incremental capital, and Gilead is now putting more money into unvalidated acquisitions, which discounts that sub-item. A positive assessment of “excellent unit economics, but unproven incremental capital returns” is fair. It recognizes the real high-quality cash generation without ignoring the unresolved question of whether the money is being spent well.

  Jun 11, 2026
• QWhat conditions would have to hold simultaneously for it to rise fivefold in ten years? Are those conditions realistic? What expectations are embedded in today's share price?2/10

  A

  For Gilead to rise fivefold in ten years, several difficult conditions would need to hold at the same time, and that is badly mismatched with its fundamental profile. The realism is low. Today's share price, about $122, does not embed wildly optimistic expectations of a fivefold return in ten years. It embeds a moderate valuation for a reasonably mature pharmaceutical company with some growth options. After the share price fell from the report snapshot of $130.5, valuation tension eased somewhat, but a fivefold outcome is still outside reasonable expectations.

  First, make explicit the two hidden premises in this linked question: what conditions need to hold for a fivefold return in ten years, and what today's share price implies.

  Conditions that must all hold for a fivefold return in ten years, with none missing:

  1. The HIV base must not only hold, but keep growing. In reality, Biktarvy, a daily oral drug, faces migration pressure from ViiV/GSK's long-acting injectables, with Cabenuva up +42% in 2025. Simply defending the base is already hard; sustained high growth is difficult.
  2. Long-acting prevention, Yeztugo, must scale to the upper end of peak expectations. This is the most imaginative line, but even if it reaches analysts' optimistic peak of about $8 billion, versus current 2026 guidance of only $1 billion, it would lift the total revenue base of about $29.4 billion by only a bit more than 20%. It cannot support a fivefold return by itself.
  3. The roughly $11.8 billion of 2026 acquired assets must almost all deliver. anito-cel, ADCs, bispecific antibodies, and other transactions would need broad clinical, approval, and commercialization success, growing into new multibillion-dollar cash cows. This is highly uncertain, and industry failure rates are high.
  4. The valuation multiple must expand sharply. The current static PE is about 17 times. If revenue grows only moderately, a fivefold return would require the PE to expand from 17 times to above 30 times. That would require the market to re-rate Gilead as a high-growth platform, not a mature pharmaceutical company.

  Multiplying those four conditions shows that a fivefold return in ten years requires a low-probability combination of textbook multi-engine breakout plus major re-rating. Gilead's real growth profile is 2026 guidance of 5–6% revenue growth and about 2% four-year historical compound growth. For a mature pharmaceutical company growing in the single digits, a fivefold return in ten years, requiring about 17% annualized, is unrealistic both mathematically and fundamentally. This must be scored low honestly. It would be wrong to pretend the conditions are easy just to fit an LTGG narrative.

  What expectations are embedded in today's share price? Key facts: the report snapshot was $130.5 on May 22, 2026, market cap about $163.6 billion, and PE about 17.8 times. As of June 10, 2026, the share price had fallen to about $122, market cap about $151.5 billion, and PE about 17 times. Based on the report's conservative shareholder return estimate, Gilead's Owner Earnings yield is a little above 5%, and its free cash flow yield is about 5.8%, while the U.S. 10-year Treasury yield was about 4.48% in May 2026. In other words, the market is pricing Gilead for a modest premium over the risk-free rate: stable cash flow plus some growth options. It is not pricing an explosive fivefold outcome in ten years. The report judged $130.5 to be closer to the upper end of fair value and to have partly prepaid for the future. After the share price fell to $122, relative to the report's neutral intrinsic-value range of $100–125 per share, it moved from “expensive near the upper end” back to “upper part of the range.” The valuation feels less stretched, but it is still not obviously cheap.

  From a Baillie Gifford perspective, this is where Gilead looks least like an LTGG candidate. The simultaneous conditions required for a fivefold return in ten years are unrealistic, and the current share price is not pricing a fivefold outcome anyway; it is pricing a steady pharmaceutical company. The honest conclusion is that today's buyer of Gilead can expect low-single-digit to mid-single-digit annualized returns, with the report giving conservative 2–4%, neutral 5–7%, and optimistic 8–10%, rather than fivefold growth returns. This item deserves a clear low score.

  Jun 11, 2026
• QWhy has the market not realized all this yet? Is it because the market does not understand, looks down on it, or cannot look far enough? What will become the “narrative inflection point”?3/10

  A

  Honestly, the market has not misread Gilead. It is neither an overlooked hidden gem nor a wrongly punished undervalued stock. The market is already reasonably pricing it as a high-quality mature pharmaceutical company with stable cash flow, a real HIV moat, and some growth options. So the truthful answer for Gilead is not that the market does not understand, looks down on it, or cannot look far enough. The market sees it fairly clearly, and valuation is broadly appropriate. The only possible perception gap lies in the peak potential of long-acting prevention and the success or failure of acquisition integration. Those two points are also the future narrative inflection points.

  Use the three lenses of “does not understand / looks down on it / cannot look far enough” one by one to check whether the market is obviously wrong:

  • Does not understand? Largely no. Gilead is a mature commercial pharmaceutical company with transparent financial statements, a clear product portfolio, and visible cash flow, including 2025 operating cash flow of $10.019 billion. Many sell-side analysts cover it. This is not a story hidden in a complex structure that nobody can understand. The market understands the business quite well.
  • Looks down on it? Not really. The current static PE is about 17 times, and market cap is about $151.5 billion. That is not a distressed valuation for a problem stock. The report's cross-sectional comparison also shows that relative to BMY at about 16.7 times PE it is more expensive, relative to MRK it is cheaper, and relative to ABBV it sits in the middle. The market places it in a “reasonable to high” position, not at a rejected discount. It is clearly not being looked down on.
  • Cannot look far enough? This is the only possible direction for a perception gap, but it is more likely two-sided. On one hand, the market may be underestimating the long-tail peak of long-acting prevention Yeztugo, with Mizuho at about $8 billion and Citi estimating that Gilead's PrEP portfolio could take 60%+ share in the U.S. If that line delivers, the perception gap is upward. On the other hand, the market may also be underestimating integration risk and impairment potential from the roughly $11.8 billion of 2026 acquisitions. If management overpays or buys the wrong assets, the perception gap is downward. These two directions offset each other, making it hard to argue that the market is systematically wrong in one clear direction.

  So contrary to the premise of “why has the market not realized all this yet,” I have to say honestly that for Gilead there is no obvious undervalued truth being ignored by the market and waiting to be discovered. If it is undervalued at all, it is not an event-driven mispricing; it is simply not cheap enough. The report itself rates it Watch and says the current price is closer to the upper end of the fair range, not obviously cheap. Forcing it into a story of an overlooked treasure the market does not understand would be dishonest.

  What will become the “narrative inflection point”? Since the perception gap is concentrated in long-acting prevention and acquisitions, the inflection points will come from those being confirmed or falsified:

  • Upside inflection: Yeztugo scales far above expectations, well beyond 2026 guidance of $1 billion and rapidly toward peak potential, or oncology assets such as anito-cel/Trodelvy produce major data and scale commercially. The market would re-rate Gilead from mature pharma to a platform with a second growth curve, lifting the PE.
  • Downside inflection: Biktarvy growth is steadily eroded by long-acting competitors such as ViiV Cabenuva, which grew +42%, or the 2026 acquisitions suffer serial impairments and ROIC falls materially. The market would mark it back down to an ordinary mature pharmaceutical company, or even to a failed capital allocator. In the report's warning-case scenario, 40%–50% downside in the share price is not unimaginable.

  From a Baillie Gifford perspective, the standard answer to “why has the market not realized it” is to identify an underestimated truth. Gilead's honest answer is precisely that there is no such obvious truth. The market sees it clearly, valuation is about right, and perception gaps are small and two-sided. This dimension lacks the large and directionally clear perception gap LTGG values most, so it should score low. The real question is not whether the market is wrong, but which happens first: long-acting prevention and acquisition integration delivering, or disappointment. That will decide whether it is re-rated upward or marked back down.

  Jun 11, 2026